Search Results - "Stintzing, S"

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group by Modest, D.P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L.F., Giessen-Jung, C., Stahler, A., Schmoll, H.J., Jung, A., Kirchner, T., Tannapfel, A., Reinacher-Schick, A.

“…To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving…”
Get full text

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial by Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., Heinemann, V.

“…FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients…”
Get full text

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study by Stintzing, S, Miller-Phillips, L, Modest, D.P, Fischer von Weikersthal, L, Decker, T, Kiani, A, Vehling-Kaiser, U, Al-Batran, S.-E, Heintges, T, Kahl, C, Seipelt, G, Kullmann, F, Stauch, M, Scheithauer, W, Held, S, Moehler, M, Jagenburg, A, Kirchner, T, Jung, A, Heinemann, V

“…Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil,…”
Get full text

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade by Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L., Na, I-K.

“…Immunostimulatory regimens are a game changer in the fight against cancer, but still only a minority of patients achieve clinical benefit. Combination with…”
Get full text

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer by Sommerhäuser, G, Kurreck, A, Stintzing, S, Heinemann, V, von Weikersthal, L Fischer, Dechow, T, Kaiser, F, Karthaus, M, Schwaner, I, Fuchs, M, König, A, Roderburg, C, Hoyer, I, Quante, M, Kiani, A, Fruehauf, S, Müller, L, Reinacher-Schick, A, Ettrich, T J, Stahler, A, Modest, D P

“…Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with…”
Get full text

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) by Holch, J.W., Held, S., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., von Einem, J.C., Michl, M., Heinemann, V.

“…Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for…”
Get full text

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial by von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., Modest, D. P.

“…Purpose AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab,…”
Get full text

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer by Sunakawa, Y, Bekaii-Saab, T, Stintzing, S

“…Highlights • We review maintenance treatment in metastatic colorectal cancer. • We review current evidence for the clinical benefit of intermittent versus…”
Get full text

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials by Berger, M.D., Stintzing, S., Heinemann, V., Yang, D., Cao, S., Sunakawa, Y., Ning, Y., Matsusaka, S., Okazaki, S., Miyamoto, Y., Suenaga, M., Schirripa, M., Soni, S., Zhang, W., Falcone, A., Loupakis, F., Lenz, H.-J.

“…The MAPK-interacting kinase 1 (MKNK1) is localized downstream of the RAS/RAF/ERK and the MAP3K1/MKK/p38 signaling pathway. Through phosphorylation MKNK1…”
Get full text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 by Stintzing, S., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Jäger, E., Heintges, T., Stoll, C., Giessen, C., Modest, D.P., Neumann, J., Jung, A., Kirchner, T., Scheithauer, W., Heinemann, V.

“…The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in…”
Get full text

Color and Antioxidant Properties of Cyanidin-Based Anthocyanin Pigments by Stintzing, Florian C, Stintzing, Angela S, Carle, Reinhold, Frei, Balz, Wrolstad, Ronald E

“…A series of cyanidin-based anthocyanin pigments was investigated to determine the effect of structural variation on a number of chemical and physical…”
Get full text

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial by Modest, D.P., Jung, A., Moosmann, N., Laubender, R.P., Giessen, C., Schulz, C., Haas, M., Neumann, J., Boeck, S., Kirchner, T., Heinemann, V., Stintzing, S.

“…Our study investigated the impact of specific KRAS mutations and BRAF mutation on progression‐free survival (PFS) and overall survival (OS) in patients with…”
Get full text

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials by Sunakawa, Y., Stintzing, S., Cao, S., Heinemann, V., Cremolini, C., Falcone, A., Yang, D., Zhang, W., Ning, Y., Stremitzer, S., Matsusaka, S., Yamauchi, S., Parekh, A., Okazaki, S., Berger, M.D., Graver, S., Mendez, A., Scherer, S.J., Loupakis, F., Lenz, H.-J.

“…Tumor-associated macrophages (TAMs) with the M2-like phenotype are regulated by mainly NF-kB pathway including TBK1, which can influence tumor progression by…”
Get full text

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial) by Michl, M., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Hielscher, J., Scholz, M., Mueller, S., Lerch, M.M., Modest, D.P., Kirchner, T., Jung, A., Heinemann, V.

“…To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal…”
Get full text

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial) by Stahler, A., Heinemann, V., Giessen‐Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., Fischer von Weikersthal, L., Vehling‐Kaiser, U., Stauch, M., Quietzsch, D., Held, S., von Einem, J.C., Holch, J., Neumann, J., Kirchner, T., Jung, A., Modest, D.P.

“…Our aim was to investigate the impact of EREG and AREG mRNA expression (by RT‐qPCR) in patients with metastatic colorectal cancer (mCRC). In addition,…”
Get full text

Resection of Pulmonary Metastases from Colon and Rectal Cancer: Factors to Predict Survival Differ Regarding to the Origin of the Primary Tumor by Meimarakis, G., Spelsberg, F., Angele, M., Preissler, G., Fertmann, J., Crispin, A., Reu, S., Kalaitzis, N., Stemmler, M., Giessen, C., Heinemann, V., Stintzing, S., Hatz, R., Winter, H.

“…Background The purpose of the present study was to determine differences in prognostic factors for survival of patients with pulmonary metastases resected in…”
Get full text

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial) by Holch, J.W., Ricard, I., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., Jelas, I., Modest, D.P., Westphalen, C.B., von Einem, J.C., Michl, M., Heinemann, V.

“…Increased baseline carcinoembryonic antigen (CEA) serum level is associated with inferior overall survival (OS) in metastatic colorectal cancer (mCRC)…”
Get full text

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109) by Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C., Modest, D. P.

“…Purpose In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and…”
Get full text

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer by Sunakawa, Y., Stremitzer, S., Cao, S., Zhang, W., Yang, D., Wakatsuki, T., Ning, Y., Yamauchi, S., Stintzing, S., Sebio, A., El-khoueiry, R., Matsusaka, S., Parekh, A., Barzi, A., Azuma, M., Watanabe, M., Koizumi, W., Lenz, H.-J.

“…We provide the first evidence demonstrating that single-nucleotide polymorphisms in macrophage function-related genes may predict prognosis in locoregional…”
Get full text

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists by Büttelmann, M., Hofheinz, R.D., Kröcher, A., Ubbelohde, U., Stintzing, S., Reinacher-Schick, A., Bornhäuser, M., Folprecht, G.

“…Geriatric assessment (GA) is recommended to detect vulnerabilities for elderly cancer patients. To assess whether results of GA actually influence the…”
Get full text